Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07428044 · ClinicalTrials.gov registry record · Phase 2
A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer and Non-small Cell Lung Cancer Stage II, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 10
- Study locations
NCT07428044 is a Phase 2 study of Non-Small Cell Lung Cancer and Non-small Cell Lung Cancer Stage II that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 14 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (98% lower). The trial reports 10 study locations across 5 states.
The verdict
NCT07428044, a Phase 2 study of Non-Small Cell Lung Cancer and Non-small Cell Lung Cancer Stage II, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to find out how many people with HER2-amplified or HER2-mutated non-small cell lung cancer (NSCLC) experience a decrease in tumor viability when they receive trastuzumab deruxtecan before routine surgery to remove tumors.
Conditions Studied
Interventions
- DRUG Trastuzumab Deruxtecan
Study Locations (10)
New York
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activites) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activites) - Rockville Centre
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Michigan
- University of Michigan (Data Collection Only) - Ann Arbor
Minnesota
- Mayo Clinic (Data Collection Only) - Rochester
Quebec
- Centre Hospitalier de l'Université de Montreal (Data Collection Only) - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2026-02-13 |
| Est. Completion | 2027-02-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07428044
The ClinicalTrials.gov registry entry for NCT07428044 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Trastuzumab Deruxtecan is the first listed.
NCT07428044 reports 10 study locations spanning 5 distinct geographic areas - top geographies include New York, New Jersey, Michigan.
Frequently Asked Questions
What is clinical trial NCT07428044 about?
NCT07428044 is a clinical study titled "A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer". The purpose of this study is to find out how many people with HER2-amplified or HER2-mutated non-small cell lung cancer (NSCLC) experience a decrease in tumor viability when they receive trastuzumab deruxtecan before routine surgery to remove tumors.
What is the current status of trial NCT07428044?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2026-02-13. Estimated completion is 2027-02-13.
What conditions does trial NCT07428044 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer Stage II, Non-Small Cell Lung Cancer Stage IIIA, Non-Small Cell Lung Cancer Stage IIIB.
What interventions are being tested in trial NCT07428044?
The interventions under investigation include: Trastuzumab Deruxtecan (DRUG).
Who is sponsoring clinical trial NCT07428044?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07428044 being conducted?
This trial has 10 study locations across Michigan, Minnesota, New Jersey, New York, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Non-Small Cell Lung Cancer
All registered trials for this condition
Non-small Cell Lung Cancer Stage II
All registered trials for this condition
Michigan
All trials with a study site in Michigan
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.